3Q EARNINGS: Merck pursues growth as sales decline
This article was originally published in Scrip
Executive Summary
Merck & Co's third quarter 2014 sales dipped 4% on a year-over-year basis and at $10.6bn the total was slightly below market consensus of $10.68bn, so the company's stock took a small hit on 27 October as investors focused on Merck's strategy to return to growth, which is led by the recently approved cancer immunotherapy Keytruda (pembrolizumab).